TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03983785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: In pilates group: Pilates training twice a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic taping
Description: Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List
Study: NCT03081091

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The needles used for the treatments will be single-use needles of two different gauge sizes. One size or the other will be used depending on the area to be treated and the physical condition of the patient. The needles and gauge sizes used in the study are as follows:~Dong Bang siliconized needle 0.25 mm x 40 mm Dong Bang siliconized needle 0.20 mm x 30 mm~The therapist will assess the patient's condition according to traditional Chinese medicine and will look at the relationship between the patient's most affected areas and the paths of the acupuncture meridians. Subsequently, the combination of Yuan and Luo points to be treated will be determined. This procedure will be followed before every acupuncture session, in such a way that the combination of the points used will depend on the evolution of the symptoms.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body.~The Park device for the performance of sham acupuncture consists of two plastic tubes, one sliding within the other, and inside which the needle created for the device slides. The longest tube is attached to a circular base, which has an adhesive surface that sticks to the skin so that the device and the needle cannot fall. Blunt ended needles will be used for this technique and thus the needle does not get to pass through the skin but produces a cutaneous stimulation similar to conventional acupuncture needles. These needles are supplied with the kit that contains the Park sham acupuncture device and are registered in the European Union as CE 0120.
Study: NCT00359294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM00104
Description: Intravenously over 1 hour daily for 5 days, every 3 weeks.
Study: NCT01966302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS-314d-MR
Description: 15-150 mcg po BID,
Study: NCT01282333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT00371709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté-SR
Description: Paclitaxel-Eluting Coronary Stent System

Intervention type: DEVICE
Group type: OTHER
Intervention: TAXUS™ Express
Description: Paclitaxel-Eluting Coronary Stent System
Study: NCT03738761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlessa®
Description: Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Amlessa®
Description: Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-Amlessa®
Description: Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
Study: NCT00595101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03187207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03187207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03187207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03187207 Vehicle
Description: One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost Vehicle
Study: NCT00602446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: 20 mg/kg once daily orally for 6 months
Study: NCT03124537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Experimental condition
Description: This group were given the app to 1) count their steps, 2) add walks to their daily schedules, 3) create maps of their walking routes, and 4) text friends to invite them for a walk. Participants are asked to set a daily step goal and they can see how many steps they've taken each day since using the app. 2) There is an interface where participants can create maps based on walking routes. 3) They will also have the option to use a daily schedule to plan certain times in the day that they can walk. 4) The social feature gives participants the option to message friends, co-workers, or neighbors in one's contact list to invite them for a walk. They were also asked to respond to two questions twice a day about their mood and energy levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Condition Control
Description: This group received the app with the first component, the ability to count steps and set daily step goals. This group will also be able to track walks to see the time, distance, and steps of each walk, but not see these walks displayed as a map. This group will monitor their daily steps over a one-month period, and will be asked to use the app as much as possible. They were also asked to respond to two questions twice a day about their mood and energy levels.
Study: NCT02094248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO
Description: rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited \[SUNSHINE\], Shenyang, China）， 15000U/ml, s.c injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Normal saline，1ml/day, s.c injection
Study: NCT02455973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification and cardiovascular risk
Description: Group meetings will be performed in the presence of a member of the nursing staff, physiotherapy, nutrition and psychology. The meetings are weekly, lasting 1 hour and 45 minutes. In the first 1 hour and 15 minutes will be addressed health issues related to lifestyle modification (self-care, healthy eating and physical activity) using the fundamentals of motivational interviewing technique. All topics will be focused on the major cardiovascular risk factors considered modifiable.Likewise, it is envisaged to include a time of physical activity (30 minutes) oriented in conjunction with the research team. Run in: There will be a meeting with the parents in order to inform them about the participation of children in the program and guide them about the procedures of the research protocol.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: The meetings will be weekly with 45 minutes duration on a schedule of lectures about cardiovascular risk
Study: NCT01422746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500-1000 mg PO BID (X12 weeks)
Study: NCT01260272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Snack Comparator
Description: Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables. Preferred comparator snack examples include: Keebler® Cheez-It® Crackers, Fudge Shoppe ® Grasshopper® Cookies, Fudge Shoppe ® Mini Fudge Stripes ™ Cookies, Nabisco Chips Ahoy! Baked Chocolate Chip Snacks, Honey Maid Cinnamon Roll Thin Crisps, Lorna Doone Baked Shortbread Cookie Crisps, Oreo Baked Chocolate Wafer Snacks, Pepperidge Farm® Goldfish® Baked Snack Crackers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raisins
Description: Raisins are dry grape fruits that may be eaten raw, or used in cooking, baking, and brewing. Raisins are mostly composed of carbohydrates (mostly fructose). They are also high in fiber and antioxidants, relatively high in potassium, and low in sodium.
Study: NCT00594386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours.
Study: NCT02702232

Intervention type: OTHER
Intervention: Ultrasonography
Description: Ultrasonography is applied for normal subjects and patients with Parkinson's disease

Intervention type: OTHER
Intervention: Ultrasonography
Description: Ultrasonography is applied for normal subjects and patients with Parkinson's disease
Study: NCT03709121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) dosed twice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.5%)
Description: Reproxalap Ophthalmic Solution (0.5%) dosed twice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution dosed twice.
Study: NCT03756818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mivavotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study: NCT01584700

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Artery Denervation
Description: Radiofrequency ablation of the renal artery sympathetic outflow tract.
Study: NCT04573166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized atrial septostomy with combined use of radiofrequency-ablation and balloon-dilation
Description: After left and right catheterization, CURB procedure will be performed in all patients. The first step is RFA on fossae ovalis; and then graded BAS is carried out after transseptal puncture; finally, RFA is repeated around the fenestration-rim created with BAS. The fenestration-size will be determined based on the level of MLAP, and the immediate size of fenestration will be evaluated with intra-cardiac echocardiography. The patency and size of fenestration will be followed up for 6 months. During the period of follow up, the other evaluations will include the improvement in exercise tolerance, major adverse cardiac and/or cerebrovascular events (MACCE), reduction of PAWP/MLAP at rest, cardiac remodeling, myocardial injury, and so on.
Study: NCT02749799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-01 (betamethasone dipropionate) Spray, 0.05%
Description: DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
Study: NCT00823758

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: 6 to 8 participants per group.

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: 6 to 8 participants per group.

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: 6 to 8 participants per group.

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: 6 to 8 participants per group.

Intervention type: BEHAVIORAL
Intervention: Personal Interviews
Description: Conducted by phone and audiotaped.
Study: NCT01146561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: single administration of tanezumab 20 mg sub-cutaneously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single administration of placebo to match tanezumab, sub-cutaneously
Study: NCT04271540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: Tildrakizumab, a p19 inhibitor which blocks IL-23 and Th17 mediated inflammation, will be given for 6 months. As below, a baseline cardiac PET scan and echocardiogram will be performed prior to initiation and after 6 months of treatment.~Radiation: A cardiac PET scan will be performed at baseline and at 6 months~Other cardiac Imaging: An echocardiogram will be performed at baseline and at 6-months.
Study: NCT03406988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Description: Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham procedure
Description: Local injection of 0.5ml saline solution after a simulated liposuction procedure.
Study: NCT00821197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: long-limb gastric bypass
Description: Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: distal gastric bypass
Description: Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
Study: NCT01544764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment , Feedback, Incentives, and eXchange Program
Description: The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment , Feedback, Incentives, and eXchange Program
Description: The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
Study: NCT01411098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT03970499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: brain tumor resection
Description: Intraoperative brain ultrasound elastography and ultrasensitive doppler during surgery
Study: NCT02163707

Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybin
Description: Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)

Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybin
Description: Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)

Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybin
Description: Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
Study: NCT03489200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EH301
Description: 1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No intervention- placebo
Study: NCT01009255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK239512
Description: Histamine H3 Antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GSK239512
Study: NCT04505306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular Laser
Description: All treatments were performed using SPCW EndPoint 30% and 50% protocols and STMP laser. Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle. Laser was applied in the confluent mode (low intensity/high density) to cover the entire area of the macular edema and leakage as imaged by OCT and/or fundus fluorescein angiography. Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn with one burn width apart. In both groups, subthreshold power was determined by titrating burn to light (barely visible) burn and switching to either micropulse mode with 15% duty cycle or 30% and 50% EndPoint value.
Study: NCT02838576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Equine Estrogen
Description: Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
Study: NCT02174614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual (TAU)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual (TAU)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU plus Rapid Abstinence Initiation (RAI)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU plus Rapid Abstinence Initiation (RAI)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
Study: NCT04505306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular Laser
Description: All treatments were performed using SPCW EndPoint 30% and 50% protocols and STMP laser. Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle. Laser was applied in the confluent mode (low intensity/high density) to cover the entire area of the macular edema and leakage as imaged by OCT and/or fundus fluorescein angiography. Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn with one burn width apart. In both groups, subthreshold power was determined by titrating burn to light (barely visible) burn and switching to either micropulse mode with 15% duty cycle or 30% and 50% EndPoint value.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular Laser
Description: All treatments were performed using SPCW EndPoint 30% and 50% protocols and STMP laser. Patients in the STMP group were treated with the 810-nm diode micropulse scanning laser TxCell™ (IRIDEX Corporation, Mountain View, CA, USA) at 15% duty cycle. Laser was applied in the confluent mode (low intensity/high density) to cover the entire area of the macular edema and leakage as imaged by OCT and/or fundus fluorescein angiography. Patients in the SPCW group were treated with grid pattern laser with 20ms pulse PASCAL laser 532nm (TopCon Medical Laser Systems, Tokyo, Japan) with EndPoint algorithm, which was either 30% or 50% of testing burn with one burn width apart. In both groups, subthreshold power was determined by titrating burn to light (barely visible) burn and switching to either micropulse mode with 15% duty cycle or 30% and 50% EndPoint value.
Study: NCT03905538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FLT-PET/CT
Description: Dose of 0.07 mCi/Kg \[18F\]FLT to max of 5 mCi (± 20%) will be given intravenously.
Study: NCT03501654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TecnisSymfony®
Description: Patients received implantation of unilateral or bilateral TecnisSymfony® IOL after phacoemulsification by a single surgeon (MK Kim).
Study: NCT02174614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU plus RAI plus Cognitive Control Training (CCT)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.